BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Orzeyful (Oveporexton) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Orzeyful (Oveporexton)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07363720-11363@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Orzeyful (Oveporexton): Phase 3 readout est. (NCT07363720)
DESCRIPTION:Orzeyful (Oveporexton)\, phase 3\, Narcolepsy.\nStudy: A Trial 
 of TAK-861 for the Treatment of Narcolepsy With Cataplexy\nEstimated prima
 ry completion: 17 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/oveporexton#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07363720
URL:https://assetmemo.bio/drug/oveporexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05816382-11363@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Orzeyful (Oveporexton): Phase 2/3 readout est. (NCT05816382)
DESCRIPTION:Orzeyful (Oveporexton)\, phase 2/3\, Narcolepsy.\nStudy: A Stud
 y of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions\
 nEstimated primary completion: 28 February 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/oveporexton#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05816382
URL:https://assetmemo.bio/drug/oveporexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
